The weekly litigation news digest is live. Subscribe now

Further Novel Forms Of Interfering Rna Molecules - EP3222724

The patent EP3222724 was granted to Silence Therapeutics on Oct 31, 2018. The application was originally filed on Aug 5, 2003 under application number EP17160954A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3222724

SILENCE THERAPEUTICS
Application Number
EP17160954A
Filing Date
Aug 5, 2003
Status
Granted And Under Opposition
Sep 28, 2018
Publication Date
Oct 31, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALNYLAM PHARMACEUTICALSOct 31, 2018POTTER CLARKSONWITHDRAWN

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0586520
DESCRIPTIONEP0618925
DESCRIPTIONWO0044895
DESCRIPTIONWO0175164
DESCRIPTIONWO9932619
OTHEREP1527176
OTHEREP1798285
OTHEREP1857547
OTHERWO0244321
SEARCHWO02055693
SEARCHWO0244321
SEARCHWO03070912
SEARCHWO9513834

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents